Analysts expect Regentis Biomaterials Ltd. to report revenue of 0.00 for 2026, against a range of 0.00 to 0.00. The most recent reported year, 2025, came in at 0.00.
| Metric | 2025 | 2026 |
|---|---|---|
| Reported (Actual) | 0.00 | - |
| High Estimate | - | 0.00 |
| Low Estimate | - | 0.00 |
| Consensus Estimate | - | 0.00 |
Analysts expect Regentis Biomaterials Ltd. to report earnings per share of -0.63 for 2026, against a range of -0.66 to -0.60. The most recent reported year, 2025, came in at -24.16.
| Metric | 2025 | 2026 |
|---|---|---|
| Reported (Actual) | -24.16 | - |
| High Estimate | - | -0.60 |
| Low Estimate | - | -0.66 |
| Consensus Estimate | - | -0.63 |